Medical devices, healthcare technology and the business of care
PMA approval · P170035

Bausch + Lomb Ultra (samfilcon A) Contact Lenses

Bausch and Lomb, Inc., · Decision date Apr 30, 2018

MEDTECHLEDGER EXPLANATIONP170035

What did the FDA approve?

The FDA approved Bausch + Lomb Ultra (samfilcon A) contact lenses on April 30, 2018. The approval covers three lens configurations: single vision spherical, presbyopia, and astigmatism. Each is indicated for extended wear up to 7 days between removals for cleaning, disinfection, or disposal, as recommended by the eye care practitioner.

The single vision spherical lens corrects myopia and hyperopia in aphakic or non-aphakic persons with non-diseased eyes and astigmatism of 2.00 diopters or less. The presbyopia lens adds correction for presbyopia with add powers from +0.75D to +5.00D. The astigmatism lens corrects astigmatism up to 5.00 diopters. The statement reports intended use, not independent proof of safety or effectiveness.

FDA approval order statement

Approval for the Bausch + Lomb Ultra (samfilcon A) Contact Lenses. These devices are indicated for:Single Vision Spherical (SVS) Vision CorrectionThe BAUSCH + LOMB ULTRA (samfilcon A) Contact Lens is indicated for extended wear for up to 7 days between removals for cleaning and disinfection or disposal of the lens, as recommended by the eye care practitioner. The lens is indicated for the correction of refractive ametropia (myopia and hyperopia) in aphakic and/or not-aphakic persons with non-diseased eyes, exhibiting astigmatism of 2.00 diopters or less, that does not interfere with visual acuity.Presbyopia Vision CorrectionThe BAUSCH + LOMB ULTRA (samfilcon A) Contact Lens for Presbyopia is indicated for extended wear for up to 7 days between removals for cleaning and disinfection or disposal of the lens, as recommended by the eye care practitioner. The lens is indicated for the correction of refractive ametropia (myopia, hyperopia and astigmatism) and presbyopia in aphakic and/or not-aphakic persons with non-diseased eyes, exhibiting astigmatism of 2.00 diopters or less, that does not interfere with visual acuity. The lens may be prescribed for add powers ranging from +0.75D to +5.00D. Astigmatism Vision CorrectionThe BAUSCH + LOMB ULTRA (samfilcon A) Contact Lens for Astigmatism is indicated for extended wear for up to 7 days between removals for cleaning and disinfection or disposal of the lens, as recommended by the eye care practitioner. The lens is indicated for the correction of refractive ametropia (myopia, hyperopia and astigmatism) in aphakic and/or not-aphakic persons with non-diseased eyes, exhibiting astigmatism up to 5.00 diopters.
Regulatory pathway
Original PMA
Clinical specialty
Ophthalmic
Decision date
Apr 30, 2018

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P170035
Regulatory pathway
Premarket approval application
Product code
LPM
Decision code
APPR
Decision date
Apr 30, 2018
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Lenses, soft contact, extended wear.

Product code
LPM
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P170035 received

    Application receipt date recorded by FDA.

  2. P170035 · FDA decision

    APPR

  3. P170035/S021 · Related supplement

    Bausch + Lomb Ultra (samfilcon A) Contact Lenses

Timeline entries are records held by MedtechLedger for P170035. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P170035

Product / regulatory recordCompanyPathwayDecision dateSource
Bausch and Lomb, Inc.,PMA supplementSep 14, 2026FDA

Explore the linked device profile

Other records with product code LPM

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Bausch and Lomb, Inc.,

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1400 N. Goodman St., Rochester, NY, 14609

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records